SCHEMBL425915

SCHEMBL425915

CC1(C)OC(c2ccccc2)CN1C(=O)n1cnc(-c2ccc(Cl)cc2)c1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
HPGD P15428 3/20 0.38
KDM4E B2RXH2 2/20 0.38
FAAH O00519 2/20 0.38
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
MAP4K4 O95819 1/20 0.35
CES2 O00748 1/20 0.35
CTRC Q99895 1/20 0.34
SCD O00767 1/20 0.34
SCD5 Q86SK9 1/20 0.34
ADAMTS5 Q9UNA0 2/20 0.33
MMP14 P50281 1/20 0.33
CACNA1D Q01668 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425824 0.94 FAAH (0.40) HPGDFAAHCES2SCDSCD5
SCHEMBL427099 0.81 MAP4K4 (0.36) ALDH1A1HPGDKDM4EFAAHSMN1; SMN2
SCHEMBL424634 0.78 FAAH (0.42) FAAHMAPTMEN1KMT2ACES2
SCHEMBL424650 0.76 MAP4K4 (0.39) ALDH1A1HPGDKDM4EFAAHKMT2A
SCHEMBL427118 0.74 DPP4 (0.40) ALDH1A1HPGDKDM4EFAAHSMN1; SMN2
SCHEMBL425716 0.74 L3MBTL1 (0.42) ALDH1A1HPGDKDM4EFAAHMAPT
SCHEMBL7902610 0.72 FAAH (0.33) FAAHSMN1; SMN2CES2
SCHEMBL425869 0.71 FAAH (0.43) ALDH1A1HPGDKDM4EFAAHMAPT
SCHEMBL424572 0.71 MAP4K4 (0.38) ALDH1A1HPGDKDM4EFAAHMAPT
SCHEMBL427487 0.71 MAP4K4 (0.36) ALDH1A1HPGDKDM4EFAAHMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 ALDH1A1 294/4885HPGD 247/4885KDM4E 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.